Pfizer Closes Vaccines Purchase Deal With Baxter

Mnet 184432 Pfizer 1

NEW YORK (AP) — Pfizer has completed its $635 million purchase from Baxter International Inc. of two vaccines and part of the factory in Orth, Austria, where they're made.

It's part of Pfizer Inc.'s strategy for building a vaccine portfolio.

The vaccines include one against the common group C strain of meningitis, a bacterial brain infection that can kill rapidly and spread easily through respiratory and throat secretions.

The other protects against tick-borne encephalitis, a viral brain infection. It sickens thousands in Europe and Asia each year and is becoming more common.

New York-based Pfizer sells the Prevnar vaccine against pneumonia, ear infections and other diseases. It brings Pfizer more than $4 billion per year. The company also is developing vaccines against meningitis B and the bacteria Staphylococcus aureus and C. difficile.

More from

U.S. Appeals WTO Ruling Against National Meat Labels

Amazon's New Robot Army Is Ready To Ship

Oil Plunge Is Threat And Boon To Global Economies

Explore more news here.